Etodolac Pyranoindole Derivative for Specific eEF2K Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule kinase inhibitors are ineffective in inhibiting eukaryotic elongation factor 2 kinase (eEF2K), a critical driver in aggressive solid cancers, due to lack of data on its 3D crystal structure and non-specificity at low concentrations.
Innovation Solution
Development of a novel etodolac derivative with a pyranoindole structure, synthesized using EDCI as a coupling reagent, to specifically inhibit eEF2K in cancer cells through a novel core structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional kinase inhibitors are used, then general kinase activity is inhibited, but eEF2K cannot be inhibited due to lack of specific structural data
Solution Approach 1:
The patent performs preliminary computational homology modeling of eEF2K structure based on related kinases before conducting high-throughput screening. This preliminary structural model enables the design of specific inhibitors without requiring actual 3D crystal structure, resolving the contradiction by preparing necessary information in advance that would otherwise be unavailable
Solution Approach 2:
The patent creates a computational copy or model of the eEF2K kinase structure by homology modeling based on known structures of related kinases. This virtual structural copy allows drug screening and design processes to proceed without the actual physical structure, enabling specific inhibitor development while avoiding the complexity of obtaining experimental structure data
2Adaptability or versatility
If pan kinase inhibitors are used, then multiple kinases are inhibited, but eEF2K remains unaffected due to its unique structure
Solution Approach 1:
The patent identifies and targets specific local features of the eEF2K kinase domain through homology modeling, focusing on unique structural characteristics that distinguish it from other kinases. This localized targeting approach enables the design of inhibitors that specifically bind to eEF2K's unique structural features rather than general kinase conserved regions, achieving both specificity and reliability
Solution Approach 2:
The patent changes the selection parameters for inhibitor design from general kinase conserved regions to eEF2K-specific structural parameters derived from homology modeling. By adjusting the targeting parameters to focus on eEF2K's unique structural characteristics rather than universal kinase features, the patent achieves specific inhibition of eEF2K while maintaining the ability to screen through compound libraries
3Reliability
If high concentrations of inhibitors are used, then eEF2K may be inhibited, but non-specific effects increase and therapeutic index decreases
Solution Approach 1:
The patent performs preliminary computational screening using the homology model to identify compounds with high predicted binding affinity to eEF2K before testing at high concentrations. This preliminary filtering ensures that only highly specific compounds proceed to high-concentration testing, maintaining therapeutic index by preventing non-specific toxicity from the outset
Solution Approach 2:
The patent replaces physical high-throughput screening at multiple concentrations with computational virtual screening using the homology model. This substitution allows identification of high-potency, high-specificity compounds in silico before experimental validation, reducing the need for high-concentration testing and associated non-specific toxicity
Data Source
AI summary
A compound derivative is provided, where R in the compound of formula A is (2-(2-(piperidin-1-yl)ethane-1-amine), and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.